Outcome of coronary plaque burden: a 10-year follow-up of aggressive medical management

Estimation of left ventricular (LV) mass has both prognostic and therapeutic value independent of traditional risk factors. Unfortunately, LV mass evaluation has been underestimated in clinical practice. Assessment of LV mass can be performed by a number of imaging modalities. Despite inherent limitations, conventional echocardiography has fundamentally been established as most widely used diagnostic tool. 3-dimensional echocardiography (3DE) is now feasible, fast and accurate for LV mass evaluation. 3DE is also superior to conventional echocardiography in terms of LV mass assessment, especially in patients with abnormal LV geometry. Cardiovascular magnetic resonance (CMR) and cardiovascular computed tomography (CCT) are currently performed for LV mass assessment and also do not depend on cardiac geometry and display 3-dimensional data, as well. Therefore, CMR is being increasingly employed and is at the present standard of reference in the clinical setting. Although each method demonstrates advantages over another, there are also disadvantages to receive attention. Diagnostic accuracy of methods will also be increased with the introduction of more advanced systems. It is also likely that in the coming years new and more accurate diagnostic tests will become available. In particular, CMR and CCT have been intersecting hot topic between cardiology and radiology clinics. Thus, good communication and collaboration between two specialties is required for selection of an appropriate test.     

Pregnancy outcome in women with polycystic ovary syndrome comparing the effects of laparoscopic ovarian drilling and clomiphene citrate stimulation in women pre-treated with metformin: a retrospective study

Background  

Ovarian stimulation in women with polycystic ovary syndrome (PCOS) increases the risk for perinatal complications. Ovulation induction by laparoscopic ovarian drilling (LOD) might improve the overall pregnancy outcomes. The aim of our study was to assess the adverse events or effects on pregnancy of LOD and clomiphene citrate (CC) stimulation in patients who received metformin.     

The N Terminus of Phosphodiesterase TbrPDEB1 of Trypanosoma brucei Contains the Signal for Integration into the Flagellar Skeleton

The precise subcellular localization of the components of the cyclic AMP (cAMP) signaling pathways is a crucial aspect of eukaryotic intracellular signaling. In the human pathogen Trypanosoma brucei, the strict control of cAMP levels by cAMP-specific phosphodiesterases is essential for parasite survival, both in cell culture and in the infected host. Among the five cyclic nucleotide phosphodiesterases identified in this organism, two closely related isoenzymes, T. brucei PDEB1 (TbrPDEB1) (PDEB1) and TbrPDEB2 (PDEB2) are predominantly responsible for the maintenance of cAMP levels. Despite their close sequence similarity, they are distinctly localized in the cell. PDEB1 is mostly located in the flagellum, where it forms an integral part of the flagellar skeleton. PDEB2 is mainly located in the cell body, and only a minor part of the protein localizes to the flagellum. The current study, using transfection of procyclic trypanosomes with green fluorescent protein (GFP) reporters, demonstrates that the N termini of the two enzymes are essential for determining their final subcellular localization. The first 70 amino acids of PDEB1 are sufficient to specifically direct a GFP reporter to the flagellum and to lead to its detergent-resistant integration into the flagellar skeleton. In contrast, the analogous region of PDEB2 causes the GFP reporter to reside predominantly in the cell body. Mutagenesis of selected residues in the N-terminal region of PDEB2 demonstrated that single amino acid changes are sufficient to redirect the reporter from a cell body location to stable integration into the flagellar skeleton.In eukaryotes, the ubiquitous second messenger cyclic AMP (cAMP) is generated from ATP by membrane-integral or by cytoplasmic, CO₂-regulated cyclases (35, 44). The cAMP signal is processed by a small group of receiver proteins, including the regulatory subunit of protein kinase A (28), cAMP-gated ion channels (4), and the guanine-nucleotide-exchange proteins EPAC1 and EPAC2 (39). The cAMP signal is terminated by the action of a family of cyclic nucleotide-specific phosphodiesterases (PDEs) (9). This paradigm is rather straightforward, involves a limited number of players, and is generally well understood, at least in mammalian cells. However, much less is known about how individual cAMP signals are temporally and spatially controlled. Since most eukaryotic adenylyl cyclases are integral membrane proteins, often restricted to specific membrane subdomains (10), cAMP signaling is usually initiated at the cell membrane (40). However, diffusion of cAMP away from its site of generation is rapid, with diffusion coefficients being about 400 μm²/s (8, 15, 29), translating into diffusion velocities of 30 to 40 μm/s. As a consequence, the signal would reach the center of the cell with a diameter of 3 μm within less than 50 ms and would rapidly saturate the entire cell. While regulation through fluctuating cellular levels of cAMP represents a valid paradigm of cAMP signaling, it has become clear that other, more localized modes of cAMP signaling must also exist. Several groups have shown that the cAMP response of a given cell can differ depending on what set of receptors activates the cyclase response (14, 30, 41, 42). Similarly, the cAMP response of endothelial cells depends on the subcellular site where the cAMP is produced. They tighten their barrier function when cAMP is produced by membrane-bound adenylyl cyclases but become more permeable when cAMP is produced in the cytoplasm (17, 45). The distinct subcellular localization of cAMP signals was experimentally demonstrated using an array of techniques (29, 40, 55, 56).Physically tethered PDEs might serve to confine newly synthesized cAMP to defined microdomains. Only cAMP-binding proteins that are localized within or extend into such microdomains would be able to receive the cAMP signal (17, 49). cAMP concentrations within such domains might rise and fall rapidly, reaching peak concentrations much more rapidly and locally far beyond the steady-state cAMP levels measured in whole-cell extracts. Such spatially organized, tethered PDEs can generate local sinks into which cAMP disappears (1, 23). This paradigm would allow the simultaneous presence of numerous local cAMP concentration gradients within a single cell, allowing great flexibility in signal generation and intracellular signal transmission. This concept is based on the distinct subcellular localization and physical association of PDEs with subcellular structures and on the existence of localized subcellular cAMP pools, for which there is extensive experimental support (3, 5, 13, 50, 52). Interestingly, PDEs localized in different subcellular regions may still be able to compensate for each other. Ablation of the cilium-specific PDE1C from the olfactory neurons in the mouse did not prolong response termination, as long as the cytoplasmic PDE4 in the cell body was still present (11).The unicellular eukaryote Trypanosoma brucei is the causative agent of human sleeping sickness in sub-Saharan Africa. It belongs to the large order of the kinetoplastida, which includes many medically and economically important pathogens of humans, their livestock, and their crops worldwide (27). Trypanosomes are very small cells (about 15 by 3 μm in diameter) that carry a single flagellum (10 by 0.5 μm). The volume of a procyclic trypanosome of strain 427 is (9.6 ± 0.8) × 10⁻¹⁴ liter (Markus Engstler, personal communication), with the flagellum representing about 15% of this. A signaling threshold concentration of 1 μM cAMP corresponds to just about 30,000 molecules of cAMP per cell. Given a diffusion coefficient of 400 μm²/s (29), unrestricted diffusion of cAMP would swamp the cell within 50 ms. Obviously, temporal and spatial control of cAMP signaling is crucial for T. brucei. Strategically located, physically tethered PDEs might thus play an important role in the architecture of the cAMP signaling pathways in T. brucei.The genomes of T. brucei and of other kinetoplastids, such as T. vivax, T. cruzi, Leishmania major, L. infantum, and L. braziliensis, all code for the same set of five cyclic nucleotide-specific PDEs (25, 53). In T. brucei, the genes for T. brucei PDEB1 (TbrPDEB1; subsequently termed PDEB1) and TbrPDEB2 (PDEB2) are tandemly arranged on chromosome 9 and code for two very similar cAMP-specific PDEs, each with two GAF (mammalian cyclic GMP-dependent PDEs, Anabaena adenylyl cyclases, Escherichia coli FhlA) domains (21) in their N-terminal regions (38, 57). These two PDEs were also studied experimentally in T. cruzi (12) and L. major (24, 52), and orthologues are present in all kinetoplastid genomes available so far. Despite their high overall sequence similarity, PDEB1 and PDEB2 exhibit distinct subcellular localizations (31). PDEB1 is predominantly found in the flagellum, where it is stably associated with cytoskeletal components that are resistant to detergent extraction. In contrast, PDEB2 is mostly localized in the cell body, from where it is fully extractable by nonionic detergents. However, a minor fraction of PDEB2 also associates with the flagellar skeleton in a Triton-resistant manner, most likely through interaction with PDEB1. Earlier work has shown that both PDEB1and PDEB2 are essential enzymes in bloodstream-form T. brucei (31), while TbPDEA, TbPDEC, and TbPDED play minor roles (20; S. Kunz, unpublished data).     

Sequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In Vivo

Protein aggregation, arising from the failure of the cell to regulate the synthesis or degradation of aggregation-prone proteins, underlies many neurodegenerative disorders. However, the balance between the synthesis, clearance, and assembly of misfolded proteins into neurotoxic aggregates remains poorly understood. Here we study the effects of modulating this balance for the amyloid-beta (Aβ) peptide by using a small engineered binding protein (Z_Aβ3) that binds with nanomolar affinity to Aβ, completely sequestering the aggregation-prone regions of the peptide and preventing its aggregation. Co-expression of Z_Aβ3 in the brains of Drosophila melanogaster expressing either Aβ₄₂ or the aggressive familial associated E22G variant of Aβ₄₂ abolishes their neurotoxic effects. Biochemical analysis indicates that monomer Aβ binding results in degradation of the peptide in vivo. Complementary biophysical studies emphasize the dynamic nature of Aβ aggregation and reveal that Z_Aβ3 not only inhibits the initial association of Aβ monomers into oligomers or fibrils, but also dissociates pre-formed oligomeric aggregates and, although very slowly, amyloid fibrils. Toxic effects of peptide aggregation in vivo can therefore be eliminated by sequestration of hydrophobic regions in monomeric peptides, even when these are extremely aggregation prone. Our studies also underline how a combination of in vivo and in vitro experiments provide mechanistic insight with regard to the relationship between protein aggregation and clearance and show that engineered binding proteins may provide powerful tools with which to address the physiological and pathological consequences of protein aggregation.     

Patenting of university and non-university public research organisations in Germany: evidence from patent applications for medical research results

Background

Patents are one of the most important forms of intellectual property. They grant a time-limited exclusivity on the use of an invention allowing the recuperation of research costs. The use of patents is fiercely debated for medical innovation and especially controversial for publicly funded research, where the patent holder is an institution accountable to public interest. Despite this controversy, for the situation in Germany almost no empirical information exists. The purpose of this study is to examine the amount, types and trends of patent applications for health products submitted by German public research organisations.

Methods/Principal Findings

We conducted a systematic search for patent documents using the publicly accessible database search interface of the German Patent and Trademark Office. We defined keywords and search criteria and developed search patterns for the database request. We retrieved documents with application date between 1988 and 2006 and processed the collected data stepwise to compile the most relevant documents in patent families for further analysis. We developed a rationale and present individual steps of a systematic method to request and process patent data from a publicly accessible database. We retrieved and processed 10194 patent documents. Out of these, we identified 1772 relevant patent families, applied for by 193 different universities and non-university public research organisations. 827 (47%) of these patent families contained granted patents. The number of patent applications submitted by universities and university-affiliated institutions more than tripled since the introduction of legal reforms in 2002, constituting almost half of all patent applications and accounting for most of the post-reform increase. Patenting of most non-university public research organisations remained stable.

Conclusions

We search, process and analyse patent applications from publicly accessible databases. Internationally mounting evidence questions the viability of policies to increase commercial exploitation of publicly funded research results. To evaluate the outcome of research policies a transparent evidence base for public debate is needed in Germany.     

Binding of phosphorylated peptides and inhibition of their interaction with disease‐relevant human proteins by synthetic metal‐chelate receptors

The modulation of biological signal transduction pathways by masking phosphorylated amino acid residues represents a viable route toward pharmacologic protein regulation. Binding of phosphorylated amino acid residues has been achieved with synthetic metal‐chelate receptors. The affinity and selectivity of such receptors can be enhanced if combined with a second binding site. We demonstrate this principle with a series of synthetic ditopic metal‐chelate receptors, which were synthesized and investigated for their binding affinity to phosphorylated short peptides under conditions of physiological pH. The compounds showing highest affinity were subsequently used to inhibit the interaction of the human STAT1 protein to a peptide derived from the interferon‐γ receptor, and between the checkpoint kinase Chk2 and its preferred binding motif. Two of the investigated ditopic synthetic receptors show a significant increase in inhibition activity. The results show that regulation of protein function by binding to phosphorylated amino acids is possible. The introduction of additional binding sites into the synthetic receptors increases their affinity, but the flexibility of the structures investigated so far prohibited stringent amino acid sequence selectivity in peptide binding. Copyright © 2009 John Wiley & Sons, Ltd.